

Decision Date	Reference Number	Jurisdiction	Active Ingredient	Product Presentation	Indication	Status Reason
25/07/2023	MAP23-0051448	VIC	Psilocybine	Capsule	Treatment resistant depression	Expired
2/11/2023	MAP23-0053822	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
2/11/2023	MAP23-0053821	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
7/12/2023	MAP23-0059833	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
7/12/2023	MAP23-0058571	VIC	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
7/12/2023	MAP23-0059840	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
23/01/2024	MAP23-0061633	WA	Psilocybine	Capsule	Treatment resistant depression	Approved
2/10/2024	MAP24-0079480	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
2/10/2024	MAP24-0079490	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
2/10/2024	MAP24-0079536	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
2/10/2024	MAP24-0079436	VIC	Psilocybine	Capsule	Treatment resistant depression	Approved
21/10/2024	MAP24-0074718	SA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
14/11/2024	MAP24-0065129	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
19/11/2024	MAP24-0082455	WA	Psilocybine	Capsule	Treatment resistant depression	Approved
21/11/2024	MAP24-0083179	WA	Psilocybine	Capsule	Treatment resistant depression	Approved
21/11/2024	MAP24-0083178	WA	Psilocybine	Capsule	Treatment resistant depression	Approved
28/11/2024	MAP24-0083391	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
28/11/2024	MAP24-0083392	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
13/12/2024	MAP24-0084262	QLD	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
18/12/2024	MAP24-0085266	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
19/12/2024	MAP24-0084481	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
19/12/2024	MAP24-0084256	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
2/01/2025	MAP24-0084458	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
5/02/2025	MAP24-0076394	ACT	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
17/02/2025	MAP24-0083985	QLD	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
14/03/2025	MAP25-0088913	QLD	Psilocybine	Capsule	Treatment resistant depression	Approved
16/04/2025	MAP25-0088215	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
16/04/2025	MAP25-0088214	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
23/04/2025	MAP24-0085265	VIC	Psilocybine	Capsule	Treatment resistant depression	Approved
28/04/2025	MAP25-0089016	QLD	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
28/04/2025	MAP25-0089023	QLD	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
8/05/2025	MAP23-0059337	WA	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
17/06/2025	MAP25-0096360	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
19/06/2025	MAP25-0096468	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
19/06/2025	MAP25-0096752	NSW	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved
25/06/2025	MAP25-0093876	NSW	Psilocybine	Capsule	Treatment resistant depression	Approved
29/06/2025	MAP23-0061103	VIC	Psilocybine	Capsule	Treatment resistant depression	Approved
	MAP25-0097375	VIC	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Awaiting Decision
	MAP25-0097376	VIC	Psilocybine	Capsule	Treatment resistant depression	Awaiting Decision
	MAP23-0061976	VIC	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Withdrawn
	MAP23-0061970	VIC	Psilocybine	Capsule	Treatment resistant depression	Withdrawn

Notes:

The 'Expired' application MAP23-0051448 has been included as it was approved during the provided date range; it has since expired.

Both 'Withdrawn' applications were originally approved on 30/01/2024 but were withdrawn during the provided date range. The 'Decision Date' field is made blank when an application is withdrawn.

Pending applications are designated as 'Awaiting Decision'. These applications were not approved during the provided date range.